Adjusting Overall Survival Estimates of Macitentan in Pulmonary Arterial Hypertension After Treatment Switching: Results from the SERAPHIN Study.

Di Scala, Lilla; Bacchi, Marisa; Bayer, Bjørn; Turricchia, Stefano

Di Scala, Lilla; Bacchi, Marisa; Bayer, Bjørn; Turricchia, Stefano.

Afiliação

Di Scala L; Market Access, Janssen, Actelion Pharmaceuticals Ltd, 4123, Allschwil, Switzerland. ldiscala@its.jnj.com.
Bacchi M; Statistics and Decision Sciences, Global Development, Actelion Pharmaceuticals Ltd, 4123, Allschwil, Switzerland.
Bayer B; Global Market Access and Pricing, Actelion Pharmaceuticals Ltd, 4123, Allschwil, Switzerland.
Turricchia S; Global Medical Affairs, Actelion Pharmaceuticals Ltd, 4123, Allschwil, Switzerland.

Adv Ther ; 39(9): 4346-4358, 2022 09.

Article em En | MEDLINE | ID: mdl-35917059

Assuntos

Hipertensão Arterial Pulmonar; Pirimidinas; Sulfonamidas; Humanos; Hipertensão Arterial Pulmonar/tratamento farmacológico; Pirimidinas/uso terapêutico; Sulfonamidas/uso terapêutico; Resultado do Tratamento

Palavras-chave

Clinical trials; Inverse probability of censoring weighted; Macitentan; Mathematical models; Mortality; Pulmonary arterial hypertension; Rank-preserving structural failure time; Treatment switch

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Pirimidinas / Sulfonamidas / Hipertensão Arterial Pulmonar Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google